Table 5.
Diagnoses with numbers of QIs and QIs revealing non-adherence to the guidelines
| Diagnosis | n of cases with diagnosis (number of QIs) | n of QIs revealing non-adherent treatment | % QIs revealing non-adherent treatment (95% CI) | |
|---|---|---|---|---|
|
Arterial hypertension |
424 (424) |
69 |
16.3 |
(12.8-19.9) |
|
Diabetes mellitus type 2 |
174 (174) |
8 |
4.6 |
(1.5-7.7) |
|
Heart failure |
41 (89) |
27 |
30.3 |
(20.8-39.9) |
| β-Blocker |
41 (41) |
15 |
36.6 |
(21.8-51.3) |
| RAAS-I |
41 (41) |
8 |
19.5 |
(7.4-31.6) |
| Aldo-A in NYHA III/IV |
7 (7) |
4 |
57.1 |
(20.5-93.8) |
|
Atrial fibrillation |
106 (106) |
15 |
14.2 |
(7.5-20.8) |
|
Cardiovascular disease |
177 (431) |
86 |
20.0 |
(16.2-23.7) |
| Statin |
177 (177) |
53 |
29.9 |
(23.2-36.7) |
| Platelet aggregation inhibitors |
177 (177) |
12 |
6.8 |
(3.1-10.5) |
| β-blocker after myocardial infarction |
77 (77) |
21 |
27.3 |
(17.3-37.2) |
| Total* | 922 (1224) | 205 | 16.8 | (14.7-18.8) |
* The number of diagnoses exceeds the number of patients as many subjects had more than one of the target diagnoses.